Chitosan Nanoparticles for Antiviral Drug Delivery: A Novel Route for COVID-19 Treatment

被引：12

作者：

Safer, Abdel-Majed ^{[1
]}

Leporatti, Stefano ^{[2
]}

机构：

[1] Kuwait Univ, Fac Sci, Dept Biol Sci, Kuwait, Kuwait

[2] Ist Nanotecnol, CNR Nanotec, I-73100 Lecce, Italy

来源：

INTERNATIONAL JOURNAL OF NANOMEDICINE | 2021年 / 16卷

关键词：

chitosan; nanoparticles; drug delivery; antivirals; COVID-19; CHLOROQUINE; VACCINES; INHIBIT; VIRUS;

D O I：

10.2147/IJN.S332385

中图分类号：

TB3 [工程材料学];

学科分类号：

0805 ; 080502 ;

摘要：

Chitosan has been investigated in several biological fields, including drug and gene delivery, tissue engineering antiviral and immunological adjuvant methods. It's a cationic copolymer of N-acetyl glucosamine and D-glucosamine with different molecular chain lengths, compositions, and sequences than N-acetyl glucosamine and D-glucosamine. It is biocompatible and cyto-compatible, as well as recyclable and bioresorbable. As effective drug delivery methods, chitosan nanoparticles are shaped into several pathways. The purpose of this article is to provide an overview of its antiviral application as a nanocarrier for antiviral medications, highlighting the benefits, limitations, and downsides. In this review, we will report the most recent COVID-19 vaccination advances. It will also be discussed what the future holds for chitosan nanoparticles in the treatment of coronaviruses.

引用

页码：8141 / 8158

页数：18

共 50 条

[21] Chitosan Nanoparticles: A Promising System in Novel Drug Delivery
Nagpal, Kalpana
Singh, Shailendra Kumar
Mishra, Dina Nath
CHEMICAL & PHARMACEUTICAL BULLETIN, 2010, 58 (11) : 1423 - 1430
[22] Drug repurposing for the treatment of COVID-19: Targeting nafamostat to the lungs by a liposomal delivery system
Reus, Philipp
Guthmann, Hadar
Uhlig, Nadja
Agbaria, Majd
Issmail, Leila
Eberlein, Valentina
Nordling-David, Mirjam M.
Jbara-Agbaria, Doaa
Ciesek, Sandra
Bojkova, Denisa
Cinatl, Jindrich
Burger-Kentischer, Anke
Rupp, Steffen
Zaliani, Andrea
Grunwald, Thomas
Gribbon, Philip
Kannt, Aimo
Golomb, Gershon
JOURNAL OF CONTROLLED RELEASE, 2023, 364 : 654 - 671
[23] Nano-Biomimetic Drug Delivery Vehicles: Potential Approaches for COVID-19 Treatment
Witika, Bwalya A.
Makoni, Pedzisai A.
Mweetwa, Larry L.
Ntemi, Pascal V.
Chikukwa, Melissa T. R.
Matafwali, Scott K.
Mwila, Chiluba
Mudenda, Steward
Katandula, Jonathan
Walker, Roderick B.
MOLECULES, 2020, 25 (24):
[24] Brain targeted delivery of carmustine using chitosan coated nanoparticles via nasal route for glioblastoma treatment
Ahmad, Saeem
Khan, Iram
Pandit, Jayamanti
Emad, Nasr A.
Bano, Shahnaj
Dar, Khalid Imtiyaz
Rizvi, M. Moshahid Alam
Ansari, Mohd Danish
Aqil, Mohd.
Sultana, Yasmin
INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES, 2022, 221 : 435 - 445
[25] A review of the antiviral activity of Chitosan, including patented applications and its potential use against COVID-19
Jaber, Nisrein
Al-Remawi, Mayyas
Al-Akayleh, Faisal
Al-Muhtaseb, Najah
Al-Adham, Ibrahim S. I.
Collier, Phillip J.
JOURNAL OF APPLIED MICROBIOLOGY, 2022, 132 (01) : 41 - 58
[26] ANTIVIRAL SYSTEM OF INNATE IMMUNITY: COVID-19 PATHOGENESIS AND TREATMENT
Kazimirskii, A. N.
SalmaSi, J. M.
Poryadin, G., V
BULLETIN OF RUSSIAN STATE MEDICAL UNIVERSITY, 2020, (05): : 5 - 13
[27] EFFECTS OF ANTIVIRAL DRUGS ON COVID-19 TREATMENT
Luo, Min
Jia, Junbo
Wang, Ruiqi
Wang, Lin
DISCRETE AND CONTINUOUS DYNAMICAL SYSTEMS-SERIES B, 2024, 29 (05): : 2353 - 2367
[28] POTENTIAL DRUG CANDIDATES FOR TREATMENT OF COVID-19
Kumudhaveni, B.
Kathirvel, S.
Muthu, S. Deepak
Jeradsuresh, A.
Radha, R.
INTERNATIONAL JOURNAL OF PHARMACEUTICAL SCIENCES AND RESEARCH, 2020, 11 (09): : 4087 - 4094
[29] Antiviral Drug Discovery To Address the COVID-19 Pandemic
Richman, Douglas D.
MBIO, 2020, 11 (05): : 1 - 3
[30] Antiviral Efficacy of Molnupiravir for COVID-19 Treatment
Bai, Yuan
Shen, Mingwang
Zhang, Lei
VIRUSES-BASEL, 2022, 14 (04):

← 1 2 3 4 5 →